Highlights on the Treatment of High-Risk, ER+ HER2− Primary Breast Cancer

Speaker: Sherene Loi, Australia

#ESMO23: Breaking Science in Breast Cancer Video Series

Highlights on the Treatment of High-Risk, ER+ HER2− Primary Breast Cancer

Abstract discussed:

• LBA20 - A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

Series objectives: To provide oncologists all over the world with succinct summaries of the most important study results on Breast Cancer, delivered by leading experts in video interviews.

Our selection gives a landscape view of the important scientific breakthroughs in the molecular classification, prognostication and prediction, state of art management and precision oncology in Breast Cancer.

The study results covered, and speakers in this video series, have been selected exclusively by ESMO.

Published on 24 Oct 2023

Back to the Breaking Science in Breast Cancer Video Series